Adherence patterns in patients with type 2 diabetes on basal insulin analogues: Missed, mistimed and reduced doses

Current Medical Research and Opinion

Volumn 28, Issue 12, 2012, Pages 1933-1946

  Brod, Meryl ^a   Rana, Azhar ^b   Barnett, Anthony H ^c  

^a Brod Group   (United States)

^b NOVO NORDISK A S   (Denmark)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Adherence; Basal insulin; CHAID analysis; Hypoglycaemia; Insulin omission; Insulin therapy; Type 2 diabetes mellitus

Indexed keywords

GLUCOSE; INSULIN DERIVATIVE;

ADULT; ARTICLE; DRUG DOSE REDUCTION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT ATTITUDE; PATIENT COMPLIANCE; TREATMENT REFUSAL;

AGED; BLOOD GLUCOSE SELF-MONITORING; CROSS-SECTIONAL STUDIES; DATA COLLECTION; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; PATIENT COMPLIANCE;

EID: 84870426350     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2012.743458     Document Type: Article

References (35)

1. Brunton S, Gough S, Hicks D, et al. A look into the future: improving diabetes care by 2015. Curr Med Res Opin 2011;27(Suppl 3):65-72
2. Unger J. Uncovering undetected hypoglycemic events. Diabetes Metab Syndr Obes 2012;5:57-74
3. Breitscheidel L, Stamenitis S, Dippel FW, Schoffski O. Economic impact of compliance to treatment with antidiabetes medication in type 2 diabetes mel-litus: a review paper. J Med Econ 2010;13:8-15
4. Wild H. The economic rationale for adherence in the treatment of type 2 diabetes mellitus. Am J Manag Care 2012;18:S43-8
5. Currie CJ, Peyrot M, Morgan CL, et al. The impact of treatment noncompliance on mortality in people with type 2 diabetes. Diabetes Care 2012;35:1279-84
6. Donnelly LA, Morris AD, Evans JM. Adherence to insulin and its association with glycaemic control in patients with type 2 diabetes. QJM 2007;100:345-50
7. Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care 2004;27:1218-24
8. Hertz RP, Unger AN, Lustik MB. Adherence with pharmacotherapy for type 2 diabetes: a retrospective cohort study of adults with employer-sponsored health insurance. Clin Ther 2005;27:1064-73
9. Tiv M, Viel JF, Mauny F, et al. Medication adherence in type 2 diabetes: the ENTRED study 2007, a French population-based study. PLoS One 2012;7:e32412
10. Krapek K, King K, Warren SS, et al. Medication adherence and associated hemoglobin A1c in type 2 diabetes. Ann Pharmacother 2004;38:1357-62
11. Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger PM. Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study. Diabet Med 2012;29:682-9
12. Rubin RR. Adherence to pharmacologic therapy in patients with type 2 diabetes mellitus. Am J Med 2005;118(Suppl 5A):27S-34S
13. Pollack MF, Purayidathil FW, Bolge SC, Williams SA. Patient-reported toler-ability issues with oral antidiabetic agents: associations with adherence; treatment satisfaction and health-related quality of life. Diabetes Res Clin Pract 2010;87:204-10
14. Brod M, Christensen T, Bushnell DM. The impact of non-severe hypoglycemic events on daytime function and diabetes management among adults with type 1 and type 2 diabetes. J Med Econ 2012;15(5):869-77
15. Brod M, Christensen T, Bushnell DM. Impact of nocturnal hypoglycemic events on diabetes management, sleep quality, and next-day function: results from a four-country survey. J Med Econ 2012;15:77-86
16. Brod M, Christensen T, Thomsen TL, Bushnell DM. The impact of non-severe hypoglycemic events on work productivity and diabetes management. Value Health 2011;14:665-71
17. Lee WC, Balu S, Cobden D, et al. Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data. Clin Ther 2006;28:1712-25
18. Balkrishnan R, Rajagopalan R, Camacho FT, et al. Predictors of medication adherence and associated health care costs in an older population with type 2 diabetes mellitus: a longitudinal cohort study. Clin Ther 2003;25:2958-71
19. Kleinman NL, Schaneman JL, Lynch WD. The association of insulin medication possession ratio, use of insulin glargine, and health benefit costs in employees and spouses with type 2 diabetes. J Occup Environ Med 2008;50:1386-93
20. Grant RW, Wexler DJ, Watson AJ, et al. How doctors choose medications to treat type 2 diabetes: a national survey of specialists and academic gener-alists. Diabetes Care 2007;30:1448-53
21. Kass GV. An exploratory technique for investigating large quantities of categorical data. Appl Stat 1980;29:119-27
22. Magidson J. The use of the new ordinal algorithm in CHAID to target profitable segments. Database Market 1993;1:29-48
23. Cramer JA, Pugh MJ. The influence of insulin use on glycemic control: how well do adults follow prescriptions for insulin? Diabetes Care 2005;28:78-83
24. Peyrot M, Rubin RR, Kruger DF, Travis LB. Correlates of insulin injection omission. Diabetes Care 2010;33:240-5
25. Asche C, LaFleur J, Conner C. A review of diabetes treatment adherence and the association with clinical and economic outcomes. Clin Ther 2011;33:74-109
26. Khan H, Lasker SS, Chowdhury TA. Exploring reasons for very poor glycaemic control in patients with Type 2 diabetes. Prim Care Diabetes 2011;5:251-5
27. Cramer JA, Pugh MJ. The influence of insulin use on glycemic control: how well do adults follow prescriptions for insulin? Diabetes Care 2005;28:78-83
28. Fabunmi R, Nielsen LL, Quimbo R, et al. Patient characteristics, drug adherence patterns, and hypoglycemia costs for patients with type 2 diabetes mellitus newly initiated on exenatide or insulin glargine. Curr Med Res Opin 2009;25:777-86
29. Leiter LA, Yale J-F, Chiasson J-L, et al. Assessment of the impact of fear of hypoglycemic episodes on glycemic and hypoglycemia management. Can J Diabetes 2005;29:186-92
30. Wild D, von MR, Brohan E, et al. A critical review of the literature on fear of hypoglycemia in diabetes: Implications for diabetes management and patient education. Patient Educ Couns 2007;68:10-15
31. Marrett E, Radican L, Davies MJ, Zhang Q. Assessment of severity and frequency of self-reported hypoglycemia on quality of life in patients with type 2 diabetes treated with oral antihyperglycemic agents: a survey study. BMC Res Notes 2011;4:251
32. Polonsky WH, Davis CL, Jacobson AM, Anderson BJ. Hyperglycaemia, hypo-glycaemia: blood glucose control in diabetes: symptom perceptions and treatment strategies. Diabet Med 1992;9:120-5
33. Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger PM. Factors associated with injection omission/non-adherence in the Global Attitudes of Patients and Physicians in Insulin Therapy study. Diabetes Obes Metab 2012;14(12): 1081-1087
34. Egede LE, Gebregziabher M, Hunt KJ, et al. Regional, geographic, and ethnic differences in medication adherence among adults with type 2 diabetes (February). Ann Pharmacother 2011;45:169-78
35. Peeters B, Van TI, Boussery K, et al. Factors associated with medication adherence to oral hypoglycaemic agents in different ethnic groups suffering from type 2 diabetes: a systematic literature review and suggestions for further research. Diabet Med 2011;28:262-75